Table 2.
Characteristics of patients after being weighted by inverse probability of censoring/discharge at the beginning of the observation
| Regimen 1 (treated with favipiravir) | Regimen 2 (treated without favipiravir) | Standardized mean difference | |
|---|---|---|---|
| Number | 6129 | 5072 | |
| Age (years) | 66.4 (14.2) | 66.3 (14.5) | 0.008 |
| Male | 51.4% | 50.1% | 0.025 |
| Cardiovascular disease | 7.0% | 7.1% | 0.003 |
| Respiratory disease | 3.5% | 3.3% | 0.007 |
| Diabetes mellitus | 17.7% | 16.7% | 0.029 |
| Severe renal disease or dialysis | 2.2% | 2.1% | 0.005 |
| Hypertension | 37.5% | 36.5% | 0.014 |
| Obesity | 5.9% | 5.6% | 0.012 |
| Charlson comorbidity index | 0.75 (1.14) | 0.75 (1.15) | < 0.001 |
| NEWS at day 1 | 1.04 (1.22) | 1.02 (1.21) | 0.020 |
| NEWS at day 4 | 1.30 (1.47) | 1.31 (1.48) | 0.009 |
| NEWS at day 8 | 1.42 (1.77) | 1.42 (1.78) | < 0.001 |
| NEWS at day 15 | 1.70 (2.08) | 1.74 (2.13) | 0.021 |
| NEWS at day 22 | 2.0 (2.50) | 2.0 (2.48) | 0.014 |
| NEWS at day 29 | 10.22 (1.99) | 10.18 [1.99] | 0.017 |
| Fatal cases | 2.9% | 3.0% | 0.007 |
| Oxygen administration during hospitalizationa | 17.3% | 16.1% | 0.031 |
| IMV/ECMO during hospitalization | 1.0% | 0.8% | 0.013 |
| Days from symptom onset to hospitalization | 2.52 (1.64) | 2.48 (1.64) | 0.021 |
| Systemic steroid use | 18.2% | 15.9% | 0.061 |
| Remdesivir use | 6.0% | 5.8% | 0.008 |
| Tocilizumab use | 1.2% | 0.6% | 0.061 |
| Baricitinib use | 0 (0%) | 0 (0%) | < 0.001 |
Regimen 1: treated with favipiravir. Regimen 2: treated without favipiravir. Continuous valuables are presented in mean (standard deviation). Categorical variables are presented in percentage
NEWS National Early Warning Score, IMV/ECMO invasive mechanical ventilation/extracorporeal membrane oxygenation
aIndication for supplementary oxygen was judged by each physician